Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 6/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.42 |
| ▸ | RXRA | P19793 | 3/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894292 | 1.00 | NR1H2 (0.42) | NR1H2NR1H3RXRAABCB1MEN1 | |
| SCHEMBL3706217 | 1.00 | NR1H2 (0.42) | NR1H2NR1H3RXRAABCB1MEN1 | |
| SCHEMBL28956461 | 0.84 | MEN1 (0.41) | NR1H2NR1H3RXRAABCB1MEN1 | |
| SCHEMBL1729949 | 0.81 | USP2 (0.37) | NR1H2ABCB1KMT2ARORCGPR119 | |
| SCHEMBL10207129 | 0.81 | POLB (0.49) | ABCB1MEN1KMT2AUSP2TSHR | |
| SCHEMBL7900809 | 0.81 | GAA (0.40) | MEN1KMT2AUSP2TSHR | |
| SCHEMBL9235945 | 0.81 | GAA (0.40) | MEN1KMT2AUSP2TSHR | |
| SCHEMBL6822684 | 0.81 | GAA (0.40) | MEN1KMT2AUSP2TSHR | |
| SCHEMBL3728141 | 0.81 | GAA (0.40) | MEN1KMT2AUSP2TSHR | |
| SCHEMBL14897525 | 0.79 | RAB9A (0.40) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377100-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| CN-116438160-A | Carbamoyl compounds for the treatment of viral infections | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4204393-A1 | AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2023-07-05 | — | — | EP | disclosed |
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-09-29 | — | — | US | disclosed |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| WO-2020255038-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| EP-3722297-A1 | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS | Gilead Sciences, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3321265-B1 | 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AND THEIR UTILISATION AS MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190282576-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10285990-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| WO-2011133653-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20100056432-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIBACTERIAL ACTIVITY | POLYPHOR LTD. (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056432-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIBACTERIAL ACTIVITY | POLYPHOR LTD. (CH) | 2010-03-04 | — | — | US | disclosed |
| US-7582604-B2 | Template-fixed peptidomimetics with antibacterial activity | POLYPHOR LTD. (CH) | 2009-09-01 | — | — | US | disclosed |
| US-7582604-B2 | Template-fixed peptidomimetics with antibacterial activity | POLYPHOR LTD. (CH) | 2009-09-01 | — | — | US | disclosed |
| EP-1458747-B1 | TEMPLATE-FIXED PEPTIDOMIMETICS AS INHIBITORS OF SERINE PROTEASES | POLYPHOR LTD (CH) | 2009-02-11 | — | — | EP | disclosed |
| US-7417024-B2 | Template-fixed peptidomimetics as inhibitors of serine proteases | POLYPHOR LTD. (CH) | 2008-08-26 | — | — | US | disclosed |
| US-7417024-B2 | Template-fixed peptidomimetics as inhibitors of serine proteases | POLYPHOR LTD. (CH) | 2008-08-26 | — | — | US | disclosed |
| US-7253146-B2 | Template-fixed peptidomimetics with antimicrobial activity | POLYPHOR LTD (CH) | 2007-08-07 | — | — | US | disclosed |
| US-7253146-B2 | Template-fixed peptidomimetics with antimicrobial activity | POLYPHOR LTD (CH) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10285990-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | NR1H2 306/4885NR1H3 594/4885RXRA 233/4885 |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | NR1H2 306/4885NR1H3 594/4885RXRA 233/4885 |
| US-20190282576-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | NR1H2 306/4885NR1H3 594/4885RXRA 233/4885 |
| US-12377100-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | NR1H2 306/4885NR1H3 594/4885RXRA 233/4885 |
| US-20100056432-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIBACTERIAL ACTIVITY | POLL, QPCTL, PEPD | NR1H2 3876/4885NR1H3 4093/4885RXRA 1711/4885 |
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | HAVCR2, ENTPD5, HMGB3 | NR1H2 438/4885NR1H3 407/4885RXRA 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.